Compare SLQT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLQT | OBIO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 240.7M |
| IPO Year | 2020 | 2020 |
| Metric | SLQT | OBIO |
|---|---|---|
| Price | $0.92 | $3.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.88 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 1.5M | 226.8K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.00 | 33.13 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,526,594,000.00 | $33,482,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $6.14 | $12.43 |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | 15.50 | ★ 1169.22 |
| 52 Week Low | $0.56 | $2.20 |
| 52 Week High | $2.77 | $5.42 |
| Indicator | SLQT | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 46.55 |
| Support Level | $0.79 | $3.77 |
| Resistance Level | $0.94 | $4.18 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 50.29 | 41.25 |
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.